Type(s) of breast cancer-Breast carcinoma Posts on Medivizor
Navigation Menu

Type(s) of breast cancer-Breast carcinoma Posts on Medivizor

Side effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer

Posted by on Aug 25, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer.  This study concluded that these side effects do not impact the outcomes for these patients.   Some background...

Read More

Searching for patients with triple negative breast cancer to test durvalumab and olaparib

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...

Read More

Searching for patients with early stage breast cancer to trial a new radiation treatment plan

Posted by on Mar 27, 2019 in Breast cancer | 0 comments

In a nutshell The trial aims to investigate a new way of delivering radiation therapy in women with early-stage breast cancer. This will involve low doses of radiation therapy being aimed at the part of the breast where the tumor is or was. The main outcomes that will be measured are side effects and recurrence rate. This trial is recruiting in Missouri,...

Read More

Searching for patients with advanced breast cancer to trial a new medication

Posted by on Jan 8, 2019 in Breast cancer | 0 comments

In a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...

Read More

Looking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...

Read More

Looking for patients with triple negative breast cancer to test atezolizumab

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of chemotherapy and atezolizumab (Tecentriq), given before surgery, for triple negative breast cancer. The main outcomes to be measured will be response in the breast tissue and lymph nodes and survival. The details Triple negative breast cancer is not dependent on the HER2 receptors or...

Read More

Looking for patients undergoing breast core biopsy to test the effectiveness of nature sounds on anxiety reduction

Posted by on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of nature sounds to reduce pain and anxiety in patients undergoing breast core biopsy. The main outcome to be measured will be anxiety and pain scores. The study is being conducted in Chicago, Illinois, in the United States.  The details A biopsy can be a stressful test for patients...

Read More

Looking for patients with metastatic triple negative breast cancer to examine the effect of Nivolumab in combination with Cabozantinib

Posted by on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of nivolumab (Opdivo) in combination with cabozantinib (Cometriq) for metastatic triple-negative breast cancer (cancer that is not dependent on hormones or HER2 for growth). The outcome to be measured will be the response rate of the cancer to this treatment. This study is...

Read More